Search Results
Jul 19, 2026, 18:43 ET Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
range of therapeutic modalities by addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including GLP-1 therapies, while advancing innovation across high-growth areas such as oncology and other emerging indications.The planned acquisition extends
More news about: Samsung Biologics
Jul 17, 2026, 11:15 ET Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns
compounded GLP-1 medications after FDA shortages ended. The researchers also identified some suppliers that lacked sterile compounding licenses or had recent disciplinary actions related to sterile compounding practices.Does this study show that compounded GLP-1 medications
More news about: University of Colorado Anschutz
Jul 17, 2026, 08:50 ET Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
its obesity and diabetes business. Lilly has history here: Prozac reshaped the treatment of depression and powered its last great expansion before the GLP-1 era.Why Everything Else Moved TooLilly is not alone in the neighborhood. Johnson & Johnson has been building in psychedelic-adjacent
More news about: USA News Group
Jul 16, 2026, 14:19 ET US grocery slowdown enters a new phase as stretched consumers buy less -- Bain & Company analysis
use of GLP-1 weight loss medications is another factor, with users buying fewer groceries as a result, including 30% to 40% who are actively trying to cut
More news about: Bain & Company
Jul 16, 2026, 11:42 ET 30分鐘就能製作專屬微針? 怡定興生醫WINMAP™平台亮相生技展
年底完成主要市場的申請佈局，並將於本次大展首度公開實機演示，現階段優先開放學術與研究單位評估導入。新藥開發 WCC301：完成 GLP 毒理試驗，佈局全球市場在新藥開發領域，針對急性扭傷所引起的局部疼痛，怡定興生醫成功開發試驗中新藥 WCC301。其設計係藉由微針陣列精準穿透皮膚角質層，實現藥物的局部經皮遞送。目前，WCC301 已達成重要里程碑，順利完成 GLP 毒理試驗及臨床試驗用樣品生產。公司預計於今年向美國食品藥物管理局（FDA）提出新藥臨床試驗（IND）申請，並接續向台灣衛生福利部食品藥物管理署（TFDA）遞件。為縮短早期臨床時程，WCC301
More news about: 怡定興生醫
Jul 16, 2026, 11:42 ET NutraBio® Labs, Inc. Launches PROTEIN NOW!™, a Ready-to-Drink Shot Delivering 21 Grams of Protein in 3.38 Ounces
convenient, high-protein formats accelerates globally, driven by consumers seeking simpler ways to meet daily protein targets and by the rapid growth of GLP-1 medications, which have placed new emphasis on protein intake in smaller, easier-to-consume servings. PROTEIN NOW!™ addresses both with a compact shot
More news about: NutraBio Labs
Jul 16, 2026, 10:01 ET NASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market Research
GLP-1 Receptor Agonists MarketObesity GLP-1 Market
More news about: Strategic Market Research LLP
Jul 16, 2026, 09:00 ET Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse System
serve a significant population of patients with Class I and II obesity seeking a minimally invasive procedure as an alternative to chronic GLP-1 therapy or as part of a combined treatment approach.The newly cleared endomina® EZFuse system builds on this foundation with a more intuitive
More news about: Endo Tools Therapeutics (ETT)
Jul 16, 2026, 09:00 ET Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse System
designed to serve a significant population of patients with Class I and II obesity seeking a minimally invasive procedure as an alternative to chronic GLP-1 therapy or as part of a combined treatment approach.The newly cleared endomina® EZFuse system builds on this foundation with a more intuitive
More news about: Endo Tools Therapeutics (ETT)
Jul 16, 2026, 09:00 ET Endo Tools Therapeutics lève 20 millions d'euros dans le cadre d'un tour de table de série C pour déployer la technologie endomina® et la commercialisation du nouveau système endomina EZFuse
importante de patients souffrant d'obésité de classe I ou II qui recherchent une intervention mini-invasive comme alternative au traitement chronique par GLP-1 ou dans le cadre d'une approche thérapeutique combinée.Le système endomina® EZFuse, récemment homologué aux USA, s'appuie sur l'expérience collectée
More news about: Endo Tools Therapeutics (ETT)
Jul 16, 2026, 00:01 ET RESEARCH ADVANCES FROM THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
AAIC 2026, the Alzheimer's Association announced (a) a new global clinical trial combining the U.S. POINTER lifestyle intervention with a GLP-1 or similar drug, and (b) six pilot research grants to study how to bring the LatAm-FINGERS program into widespread real-world use in Latin America.
More news about: Alzheimer’s Association
Jul 15, 2026, 11:01 ET The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
one corner of medicine spills over and creates an entirely new market next door. The GLP-1 weight-loss boom is doing exactly that. As roughly 1 in 8 U.S. adults have now used a GLP-1 medication and millions reshape their bodies, a second-order demand has appeared: restoring
More news about: Equity Insider
Jul 15, 2026, 10:07 ET Lost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Insulin Injection Market ContextThe global insulin delivery device market has been undergoing structural change. Pump adoption and GLP-1 therapies have reshaped patient purchasing patterns, particularly in the United States. The complaint alleges that Embecta repeatedly
More news about: Levi & Korsinsky, LLP
Jul 15, 2026, 09:00 ET As Fertility Benefits Legislation Takes Shape, Maven Clinic Offers Employers Tools for Getting Coverage Right
Through its consumer virtual clinic, Maven provides direct access to virtual care across 30+ specialties, as well as dedicated hormone and GLP-1 care programs purpose-built for women.Founded in 2014 by CEO Kate Ryder, Maven Clinic has raised more than $425 million from leading healthcare
More news about: Maven Clinic
Jul 15, 2026, 08:45 ET As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
in GLP-1 and metabolic disease, and its shares have climbed year to date as its obesity pipeline has advanced. The relevance to MindWalk is thematic: MindWalk's LensAI platform has been applied to a GLP-1 program designed to sustain high-quality GLP-1 signaling
More news about: Equity Insider
Jul 15, 2026, 07:00 ET Withings BodyScan 2 Now Available in the US, Setting a Standard in Preventive Health and Longevity Monitoring
understand how their daily habits influence their overall metabolic wellness over time. Whether pursuing weight management goals, navigating GLP-1 treatments, or simply wanting to understand how lifestyle choices shape overall wellness, BodyScan 2 helps users monitor meaningful changes over
More news about: Withings
Jul 15, 2026, 06:00 ET Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
molecule GIPR agonist, and ASC30, an oral small molecule GLP-1R agonist, for clinical development. ASC30 and ASC48 fixed-dose combination (ASC30_48 FDC) is a potentially first-in-class oral one-pill, once-daily therapy for obesity, targeting GLP-1R and GIPR.
More news about: Ascletis Pharma Inc.
Jul 15, 2026, 06:00 ET 歌禮選定同類首創口服小分子GIPR激動劑ASC48和口服小分子GLP-1R激動劑ASC30的固定劑量復方制劑進行臨床開發
R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），和ASC30_48 FDC，ASC30（GLP-1RA）與ASC48（GIP RA）的固定劑量復方制劑（FDC），用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Jul 14, 2026, 09:01 ET US Millennials and Gen Z Are Losing Hours Each Week to Food Friction. Tempo's Cook Never Club Wants to Give It Back.
30+ grams of proteinFewer than 35 grams of carbohydrates20%+ of the daily value of fiberGLP-1 Smart, wellness forward options for those managing metabolic wellness goalsGut-friendly ingredientsSide Quests WelcomePart
More news about: Home Chef
Jul 14, 2026, 09:00 ET Mid-Year Survey: 42% of Americans Have Skipped or Delayed Medical Care in the Past Year Due to Inflation
reasons such as moving to a new state or coverage area.On GLP-1 drugs and Medicare access39% of Medicare beneficiaries say they would be interested in using GLP-1 drugs for weight loss if covered by their Medicare plan.73% of Medicare
More news about: eHealth, Inc.
Jul 14, 2026, 08:30 ET Samyang Corporation Unveils New Crystalline Dietary Fiber Brand 'Fibernova' at IFT 2026
maltodextrin to reduce sugar while maintaining the characteristic texture and flavor of gummy confectionery.With the growth of the GLP-1-related market reshaping consumer eating habits and nutritional needs, the global food industry is increasingly focusing on the development of products
More news about: Samyang Corporation
Jul 14, 2026, 06:00 ET America is Hungry for More Protein - NuCicer's High-Protein Chickpea "Nuchi" is the Answer
2026 /PRNewswire/ -- Seventy-one percent of Americans are actively trying to eat more protein, up from 59 percent three years ago. GLP-1 medications have reshaped consumers' food expectations. The global protein ingredients market is projected to reach $84 billion by 2033 while the
More news about: NuCicer
Jul 14, 2026, 05:00 ET Americans for Safe and Effective Medicines Launches to Protect Patients from Illegal Mass Compounding, Counterfeit Drugs, and Misleading Marketing
review are important when choosing a GLP-1 medication. That number rises to roughly 90 percent among current GLP-1 users.Among current GLP-1 users, the majority mistakenly believe compounded GLP-1 products are FDA approved.82 percent
More news about: Americans for Safe and Effective Medicines
Jul 13, 2026, 19:03 ET ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapiesNEW YORK, July 13, 2026 /PRNewswire/ --
More news about: Alzheimer's Drug Discovery Foundation
Jul 13, 2026, 13:00 ET COSRX Shines at VidCon 2026 With Blue Peptide-Themed Skincare Experience
is also supported by dermatologist insight around today's evolving skin concerns, including visible changes after rapid weight loss or GLP-1-related weight changes. Board-certified dermatologist Dr. Dendy Engelman notes that when weight changes quickly, skin may have less time to adapt, which
More news about: COSRX